Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis

Immune check-point in cervical cancer

(2018) F. De Felice et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial

(2018) Manish R Patel et al.   LANCET ONCOLOGY

Anti-PD-1/PD-L1 therapy for infectious diseases: learning from the cancer paradigm

(2017) Martin Rao et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade

(2017) Mark Ayers et al.   JOURNAL OF CLINICAL INVESTIGATION

Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma

(2017) Jeffrey S. Weber et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study

(2017) Van K Morris et al.   LANCET ONCOLOGY

Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial

(2017) James L Gulley et al.   LANCET ONCOLOGY

The PD-1 and PD-L1 pathway in recurrent respiratory papillomatosis

(2017) Julie Ahn et al.   LARYNGOSCOPE

Recurrent respiratory papillomatosis: A state-of-the-art review

(2017) Helena Ribeiro Fortes et al.   RESPIRATORY MEDICINE

Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer

(2017) Sanja Stevanović et al.   SCIENCE

The low-risk papillomaviruses

(2017) Nagayasu Egawa et al.   VIRUS RESEARCH

Office-Based vs Traditional Operating Room Management of Recurrent Respiratory Papillomatosis

(2017) Emel Çadalli Tatar et al.   JAMA Otolaryngology-Head & Neck Surgery

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

(2016) Howard L Kaufman et al.   LANCET ONCOLOGY

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

(2016) Robert L. Ferris et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cidofovir Efficacy in Recurrent Respiratory Papillomatosis: A Randomized, Double-Blind, Placebo-Controlled Study

(2014) J. Scott McMurray et al.   ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY

TGF  Receptor 1: An Immune Susceptibility Gene in HPV-Associated Cancer

(2014) C. Levovitz et al.   CANCER RESEARCH

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

(2014) Suzanne L. Topalian et al.   JOURNAL OF CLINICAL ONCOLOGY

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Exploiting the curative potential of adoptive T-cell therapy for cancer

(2013) Christian S. Hinrichs et al.   IMMUNOLOGICAL REVIEWS

Integration of HPV6 and Downregulation of AKR1C3 Expression Mark Malignant Transformation in a Patient with Juvenile-Onset Laryngeal Papillomatosis

(2013) Christian Ulrich Huebbers et al.   PLoS One

Immune Suppression in Premalignant Respiratory Papillomas: Enriched Functional CD4+Foxp3+ Regulatory T Cells and PD-1/PD-L1/L2 Expression

(2012) L. J. Hatam et al.   CLINICAL CANCER RESEARCH

Recurrent respiratory papillomatosis: a complex defect in immune responsiveness to human papillomavirus-6 and -11

(2010) VINCENT R. BONAGURA et al.   APMIS

Recurrent Respiratory Papillomatosis: A Review

(2009) Craig S. Derkay et al.   LARYNGOSCOPE

TGFβ in Cancer

(2008) Joan Massagué   CELL